Outlook Therapeutics Requests Type A Meeting with FDA After Second Rejection of Wet AMD Drug Bevacizumab
The road to U.S. approval for ONS-5010 has been anything but smooth. Outlook Therapeutics (New Jersey, USA) is once again…
Nanoscope Secures Major Global Wins for MCO-010 with EMA and FDA Designations
The race to restore sight for patients living with retinal degeneration just gained serious momentum. Nanoscope Therapeutics (Texas, United States)…
popular posts
